KAN.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:29):

Stats
Today's Volume	355 284
Average Volume	353 912
Market Cap	177.90M
EPS	SEK0 ( 2024-02-22 )
Next earnings date	( SEK-0.200 ) 2024-05-17
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.930
ATR14	SEK0.00600 (0.41%)

Volume Correlation

Long: -0.13 (neutral)

Short: -0.64 (weak negative)

Signal:(48.442) Neutral

Kancera AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kancera AB (publ) Correlation - Currency/Commodity

-0.21
( neutral )

-0.22
( neutral )

0.00
( neutral )

0.47
( neutral )

0.49
( neutral )

Kancera AB (publ) Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK-3.00M (0.00 %)
EPS:	SEK-0.800

Q4	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.220

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK-67 000.00 (0.00 %)
EPS:	SEK-0.130

Q2	2023
Revenue:	SEK456 000
Gross Profit:	SEK366 000 (80.26 %)
EPS:	SEK-0.220

Financial Reports:

No articles found.

Kancera AB (publ)

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.